Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88647018 |
LAW OFFICE ASSIGNED |
LAW OFFICE 103 |
MARK SECTION |
MARK |
PYLARIFY (see, http://uspto.report/TM/88647018/mark.png) |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
PYLARIFY |
OWNER SECTION (current) |
NAME |
Progenics Pharmaceuticals, Inc. |
INTERNAL ADDRESS |
47th Floor Suite J |
MAILING ADDRESS |
One World Trade Center |
CITY |
New York |
STATE |
New York |
ZIP/POSTAL CODE |
10007 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
OWNER SECTION (proposed) |
NAME |
Progenics Pharmaceuticals, Inc. |
INTERNAL ADDRESS |
47th Floor Suite J |
MAILING ADDRESS |
One World Trade Center |
CITY |
New York |
STATE |
New York |
ZIP/POSTAL CODE |
10007 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
CORRESPONDENCE INFORMATION (current) |
NAME |
PHI LAN M. TINSLEY |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
botrademarks@klgates.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
NOT PROVIDED |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
Phi Lan M. Tinsley |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
botrademarks@klgates.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
kathleen.burch@klgates.com |
DOCKET/REFERENCE NUMBER |
MIN.629.US |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Radiopharmaceutical imaging and detection agents for detection, diagnosing and monitoring cancer; pharmaceutical preparations for the
detection, diagnosis, prevention, treatment and monitoring of cancer |
GOODS OR SERVICES DELETED FROM THE APPLICATION OR INCLUDED IN A SEPARATELY FILED STATEMENT OF USE WITH A REQUEST TO
DIVIDE |
prevention, treatment |
GOODS OR SERVICES FOR WHICH APPLICANT HAS A CONTINUED BONA FIDE INTENTION, AND IS ENTITLED, TO USE |
Radiopharmaceutical imaging and detection agents for detection, diagnosing and monitoring cancer; pharmaceutical preparations for the
detection, diagnosis and monitoring of cancer |
INTERNATIONAL CLASS |
042 |
CURRENT IDENTIFICATION |
Scientific research and development in the nature of research, development and preparation of pharmaceutical drugs and imaging agents for
medical use; Providing temporary use of non-downloadable medical imaging software for the identification, quantification, diagnosis, prevention, treatment and monitoring of cancer |
GOODS OR SERVICES |
KEEP ALL LISTED |
INTERNATIONAL CLASS |
044 |
CURRENT IDENTIFICATION |
Providing medical testing services and information in the field of cancer diagnosis, treatment and prevention; Web-based medical testing for
identification, quantification, diagnostic or treatment purposes in the field of cancer; providing medical information in the field of cancer identification, diagnosis, treatment and prevention;
medical imaging services |
GOODS OR SERVICES |
KEEP ALL LISTED |
REQUEST TO DIVIDE |
YES |
EXTENSION SECTION |
EXTENSION NUMBER |
1 |
ALLOWANCE MAIL DATE |
04/21/2020 |
STATEMENT OF USE |
YES |
PAYMENT SECTION |
NUMBER OF CLASSES |
3 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
375 |
TOTAL AMOUNT |
375 |
SIGNATURE SECTION |
SIGNATURE |
/philan tinsley/ |
SIGNATORY'S NAME |
Phi Lan Tinsley |
SIGNATORY'S POSITION |
Attorney of record, Massachusetts bar member |
DATE SIGNED |
06/17/2020 |
SIGNATORY'S PHONE NUMBER |
617-261-3100 |
FILING INFORMATION |
SUBMIT DATE |
Wed Jun 17 07:54:27 ET 2020 |
TEAS STAMP |
USPTO/ESU-XXX.XXX.XX.X-20
200617075427649463-886470
18-710719bc8b39d3bca63ec1
cf77f6c8522ed0d1563c15171
ccd6db5313782fe84-DA-5426
4495-20200617074926149074 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: PYLARIFY (see, http://uspto.report/TM/88647018/mark.png)
SERIAL NUMBER: 88647018
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Progenics Pharmaceuticals, Inc., having an address of
47th Floor Suite J
One World Trade Center
New York, New York 10007
United States
Proposed: Progenics Pharmaceuticals, Inc., having an address of
47th Floor Suite J
One World Trade Center
New York, New York 10007
United States
Phone:
Fax:
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 04/21/2020.
For International Class 005:
Current identification: Radiopharmaceutical imaging and detection agents for detection, diagnosing and monitoring cancer; pharmaceutical preparations for the detection, diagnosis, prevention,
treatment and monitoring of cancer
This filing does NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified; these goods/services are either being
permanently
deleted or included in a separately filed Statement of Use with a Request to Divide: prevention, treatment
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class: Radiopharmaceutical imaging and detection agents for detection, diagnosing and monitoring cancer; pharmaceutical preparations for the detection, diagnosis and monitoring of cancer
For International Class 042:
Current identification: Scientific research and development in the nature of research, development and preparation of pharmaceutical drugs and imaging agents for medical use; Providing temporary use
of non-downloadable medical imaging software for the identification, quantification, diagnosis, prevention, treatment and monitoring of cancer
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
For International Class 044:
Current identification: Providing medical testing services and information in the field of cancer diagnosis, treatment and prevention; Web-based medical testing for identification, quantification,
diagnostic or treatment purposes in the field of cancer; providing medical information in the field of cancer identification, diagnosis, treatment and prevention; medical imaging services
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
The applicant has submitted a Request to Divide in paper or is filing a Request to Divide as part of the TEAS Allegation of Use form. This is the first extension request.
A Statement of Use has already been submitted or is being submitted along with the Extension request as evidence that applicant believes that it has made valid use of the mark in commerce. If
the USPTO finds the Statement of Use to be fatally defective, the applicant requests additional time to file an amended or substitute Statement of Use.
Correspondence Information (current):
PHI LAN M. TINSLEY
PRIMARY EMAIL FOR CORRESPONDENCE: botrademarks@klgates.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED
Correspondence Information (proposed):
Phi Lan M. Tinsley
PRIMARY EMAIL FOR CORRESPONDENCE: botrademarks@klgates.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): kathleen.burch@klgates.com
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $375 will be submitted with the form, representing payment for 3 classes.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /philan tinsley/ Date Signed: 06/17/2020
Signatory's Name: Phi Lan Tinsley
Signatory's Position: Attorney of record, Massachusetts bar member
Signatory's Phone: 617-261-3100
RAM Sale Number: 88647018
RAM Accounting Date: 06/17/2020
Serial Number: 88647018
Internet Transmission Date: Wed Jun 17 07:54:27 ET 2020
TEAS Stamp: USPTO/ESU-XXX.XXX.XX.X-20200617075427649
463-88647018-710719bc8b39d3bca63ec1cf77f
6c8522ed0d1563c15171ccd6db5313782fe84-DA
-54264495-20200617074926149074